|
|
| N (%) |
| Discontinuation | Definitive | 4 (11.1%) |
| Ocoxin treatment | 4 (11.1%) | |
| CT treatment | 4 (11.1%) | |
| Reasons for discontinuation | Death | 3 (%) |
| Serious adverse event | 1 (%) | |
| Compliance with scheduled treatment | Chemotherapy | 32 (88.9%) |
| Ocoxin | 32 (88.9%) | |
| OV vials consumed | Mean (95% CI) | 130 (118; 143) |
| Median (IQR) | 143 (137; 145) | |
| Min, Max | (14; 211) | |
| CT administration | Received all CT cycles | 32 (88.9%) |
| Delayed administration of CT cycles (≥7 days) | 4 (11.1%) | |
| CT cycles on time | 1st cycle | 36 (100%) |
| 2nd cycle | 32 (88.9%) | |
| 3rd cycle | 32 (88.9%) | |
| Regimen used | Carboplatin/paclitaxel | 36 (100%) |
| Cisplatin/paclitaxel | 0 | |
| Compliance with the evaluation time | Cycle | Median (IQR); (Min, Max) |
| Initial | 0 (0); (0;3) | |
| Cycle 1 (day 7) | 7 (2); (7; 12) | |
| Cycle 2 (day 28) | 28 (3); (28; 53) | |
| Cycle 3 (day 49) | 49 (3); (49; 77) | |
| Final (day 63) | 72.5 (6); (69; 105) |